[HTML][HTML] COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients
Background The clinical impact of severe coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in immunocompromised …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in immunocompromised …
[HTML][HTML] Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
M Treskova-Schwarzbach, L Haas, S Reda, A Pilic… - BMC medicine, 2021 - Springer
Background This study applies an umbrella review approach to summarise the global
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …
evidence on the risk of severe COVID-19 outcomes in patients with pre-existing health …
Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk… - … England Journal of …, 2022 - Mass Medical Soc
Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
L Monin, AG Laing, M Muñoz-Ruiz… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
with cancer is unknown. We aimed to assess the safety and immunogenicity of the …
[HTML][HTML] COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
[HTML][HTML] CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
EM Bange, NA Han, P Wileyto, JY Kim, S Gouma… - Nature medicine, 2021 - nature.com
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 …
[HTML][HTML] Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national …
K Maneikis, K Šablauskas, U Ringelevičiūtė… - The Lancet …, 2021 - thelancet.com
Background Haematological malignancies and their treatments are likely to affect SARS-
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …
CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …
[HTML][HTML] Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Despite therapeutic advances against SARS-CoV-2, including multiple vaccines, oral
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …
[HTML][HTML] The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
E Terpos, M Gavriatopoulou… - Blood Cancer …, 2021 - nature.com
Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …
with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …
[HTML][HTML] Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
F Malard, B Gaugler, J Gozlan, L Bouquet… - Blood cancer …, 2021 - nature.com
This study evaluated the safety and immunogenicity of BNT162b2 vaccine in patients with
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …
hematological malignancies. Antibodies blocking spike binding to immobilized ACE-2 (NAb) …